Netherlands-based biotechnology company SkylineDx announced on Sunday new data from its MERLIN_001 trial, a US study evaluating a melanoma genomic assay.
Initial results were presented at the Society for Melanoma Research Annual Meeting in New Orleans. Conducted at nine US academic sites, the study was led by three principal investigators from Moffitt Cancer Center, Mayo Clinic, and UofL Health.
The trial validated the predictive power of SkylineDx's CP-GEP Merlin test in identifying sentinel lymph node biopsy (SLNB) status in high-risk melanoma patients. Results showed the Merlin test could classify 37% of patients as Low Risk, with a negative predictive value of 92.9%. This stratification helps clinicians better determine which patients may safely avoid SLNB, reducing unnecessary procedures. The test's ability to guide treatment decisions aligns with current NCCN guidelines for melanoma management.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial